Kymera Therapeutics, Inc. ($KYMR)
Filing Information
| Accession Number | 0001193125-26-091982 |
|---|---|
| Form Type | 4 |
| Filing Date | Mar 4, 2026 |
| Document | View SEC Filing |
Transactions
9
Total Shares
65,421
Total Value
$1,091,230.62
P&L
+inf% (+$4,125,334.50)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Grant/Award | 17,650 | $0.00 | $0.00 | 245,059 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 2,039 | $87.75 | $178,924.09 | 243,020 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 1,424 | $88.50 | $126,024.57 | 241,596 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 4,113 | $89.66 | $368,760.89 | 237,483 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Mar 4, 2026 | Sale | 492 | $84.00 | $41,326.28 | 236,991 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Mar 4, 2026 | Sale | 2,519 | $85.04 | $214,206.69 | 234,472 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Mar 4, 2026 | Sale | 1,437 | $85.78 | $123,266.87 | 233,035 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Mar 4, 2026 | Sale | 447 | $86.62 | $38,721.24 | 232,588 | Direct | โ | View Details | |
Chief Financial Officer | Stock Option (Right to Buy) | Derivative | Mar 2, 2026 | Grant/Award | 35,300 | $0.00 | $0.00 | 35,300 | Direct | โ | View Details |